Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNKEUG)

Drug Name

(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid Drug Info

Synonyms

(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid; CHEMBL364748; SCHEMBL20553473; ZINC13671687; BDBM50171897; DB08760; (S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid; (S)-2-(4-Chloro-phenoxy)-3-phenyl-propionic acid

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 11460087
TTD Drug ID: DMNKEUG

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Peroxisome proliferator-activated receptor gamma (PPAR-gamma)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[2]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[3]
Lobeglitazone	DMHY3IP	Type-2 diabetes	5A11	Approved	[4]
Rosiglitazone XR	DMT45MU	Type-2 diabetes	5A11	Approved	[5]
Thiazolidinedione	DMC1NBW	Alzheimer disease	8A20	Approved	[3]
Glitazone	DMDN4A1	N. A.	N. A.	Phase 4	[6]
MURAGLITAZAR	DMG3NFZ	N. A.	N. A.	Phase 3	[7]
Rivoglitazone	DMBY31K	Ocular inflammation	9C61.24	Phase 3	[8]
Balaglitazone	DMXBHR6	Type-1 diabetes	5A10	Phase 3	[9]
Ragaglitazar	DMFSHEM	Type-1 diabetes	5A10	Phase 3	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Peroxisome proliferator-activated receptor gamma (PPAR-gamma)	TTZMAO3	PPARG_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
2	Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003 May 1;104(5):597-602.
3	Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7.
4	Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74.
5	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
6	Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
7	Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95.
8	A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Diabetes Obes Metab. 2011 Sep;13(9):806-13.
9	Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma () agonist.Mini Rev Med Chem.2012 Feb;12(2):87-97.
10	Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56.